(Reuters Health) - Even light drinkers who enjoy a single beer or glass of wine every night may still be more likely to die prematurely than people who drink less, a recent study suggests.
(Reuters Health) - An overactive immune response, which can occur with viral infections, could result in sudden hair graying, according to research in mice.
LONDON (Reuters) - Scientists have identified the core genes that are essential for the deadliest malaria parasite to survive, revealing new targets for drugs or vaccines to fight the potentially deadly disease they cause in people.
(Reuters Health) - Face masks available to consumers in China for protection against air pollution vary widely in their real-world performance, suggests a recent study.
JOHANNESBURG (Reuters) - South African gold producers agreed a 5 billion rand ($400 million) class action settlement on Thursday with law firms representing thousands of miners who contracted the fatal lung diseases silicosis and tuberculosis, officials said on Thursday.
BRUSSELS (Reuters) - The European Union's food safety watchdog urged member states on Thursday to monitor poultry products for the insecticide fipronil following the withdrawal of millions of chicken eggs from supermarket shelves last year.
JOHANNESBURG (Reuters) - South African gold producers reached a class action settlement on Thursday with law firms representing thousands of miners who contracted the fatal lung diseases silicosis and tuberculosis, the lawyers said on Thursday.
LONDON (Reuters) - British scientists have developed a far more accurate blood test to diagnose peanut allergy, offering a better way to monitor a significant food hazard.
DARMSTADT, Germany (Reuters) - The family behind Germany's Merck KGaA said it was fully committed to the diversified group's pharmaceuticals unit, even if cancer immunotherapy hopeful avelumab does not achieve blockbuster sales.
LONDON/ZURICH (Reuters) - Roche has won a reprieve from an expected wave of cheaper versions of its biotech cancer drugs as U.S. regulators knocked back a biosimilar form of rituximab from Swiss rival Novartis.